ProQR Therapeutics N.V. (FRA:0PQ)

Market Cap	141.34M -15.3%
Revenue (ttm)	13.64M -30.5%
Net Income	-45.49M
EPS	-0.43
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.337
Previous Close	1.570
Day's Range	1.337 - 1.337
52-Week Range	1.139 - 2.558
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About ProQR Therapeutics

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metab...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 187
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0PQ

Financial Performance

In 2025, ProQR Therapeutics's revenue was 16.35 million, a decrease of -16.36% compared to the previous year's 19.55 million. Losses were -42.18 million, 51.9% more than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error